Importance of invasive candidiasis in critical non neutropenic patients;Importancia de la candidiasis invasora en el enfermo crítico no neutropénico

Revista Iberoamericana de Micologia

Volumn 23, Issue 1, 2006, Pages 2-3

  Montejo, Juan Carlos ^a,b   Del Palacio, Amalia ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b Servicio de Medicina Intensiva   (Spain)

Author keywords

Candida; Critical care non neutropenic patient; Invasive candidiasis

Indexed keywords

ANTIFUNGAL AGENT;

CANDIDA; CANDIDIASIS; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE; MORTALITY; MYCOSIS; NEUTROPENIA; REVIEW;

CANDIDA;

CANDIDIASIS; CRITICAL ILLNESS; HUMANS;

EID: 32644445412     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-1406(06)70002-X     Document Type: Review

References (16)

1. Blot SL, Vauderwoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113: 480-485.
2. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents. Pharmacokinetics, safety and efficacy. Drugs 2004; 64: 1997-2000.
3. Calandra T, Marchetti O. Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clin Infect Dis 2004; 39: S185-S192.
4. Denning DW. Echinocandins: a new class of antifungal. J Antimicrob Chemother 2002; 49: 889-891.
5. García Ruíz JC, Amutio E, Pontón J. Infección fúngica invasora en pacientes inmunocomprometidos. Rev Iberoam Micol 2004; 21: 55-62.
6. Groll AH, Walsh TJ. Antifungal chemotherapy: advances and perspectives. SWISS Med Wkly 2002; 132: 303-311.
7. Jones BL, Mc Lintok LA. Impact of diagnostic markers on early antifungal therapy. Curr Opin Infect Dis 2003; 16: 521-526.
8. Leon Gil C, Leon Regidor MA, Nolla-Salas J, Sanchez Jimenez MA. Aspectos de la infección fúngica en pacientes ingresados en la Unidad de Cuidados Intensivos. Rev Clin Esp 1997; 197: 17-28.
9. Lipsett PA. Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: concepts and considerations. Clin Infect Dis 2004; 39: S193-S199.
10. Ostrosky-Zeichner L. New approaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis 2003; 16: 533-537.
11. Ostrosky-Zeichner L. Prophylaxis and treatment of invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2004; 23: 739-744.
12. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis treats. Med Mycol 2005; 43: 235-243.
13. Powers JH. Issues in clinical trials of prophylaxis of fungal infections. Clin Infect Dis 2004; 39: S211-S217.
14. Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, Pfaller M, Edwards JE Jr, Jarvis W, Dawson J, Wenzel RP. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29: 253-258.
15. Roosen J, Frans E, Wilmer A, Knockaert DC, Bobbaers H. Comparison of premorten clinical diagnoses in critically ill patients and subsegment autopsy findings. Mayo Clin Proc 2000; 75: 562-567.
16. Vincent JL, Anaissie E, Bruining H, Demajo W, el-Ebiary M, Haber J, Hiramatsu Y, Nitemberg G, Nystrom PO, Pitett D, Rogers T, Sandven P, Sganga G, Schaller MD, Solomkin J. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998; 24: 206-216.